# Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

> **NCT05969496** · PHASE2 · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 17 (estimated)

## Conditions studied

- Renal Cancer
- Kidney Cancer
- Renal Cell Carcinoma
- Inferior Vena Cava Thrombosis

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05969496
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-04
- **Primary completion:** 2026-11-01
- **Final completion:** 2029-11
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05969496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05969496, "Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05969496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*